MA50570A - Formulations de fulvestrant et méthodes d'utilisation de ces dernières - Google Patents

Formulations de fulvestrant et méthodes d'utilisation de ces dernières

Info

Publication number
MA50570A
MA50570A MA050570A MA50570A MA50570A MA 50570 A MA50570 A MA 50570A MA 050570 A MA050570 A MA 050570A MA 50570 A MA50570 A MA 50570A MA 50570 A MA50570 A MA 50570A
Authority
MA
Morocco
Prior art keywords
methods
fulvestrant formulations
fulvestrant
formulations
Prior art date
Application number
MA050570A
Other languages
English (en)
Inventor
Feng-Jing Chen
Adrian Hepner
Tara Jaskowski
Michael Joyce
Steven L Krill
Rama Abu Shmeis
Charles Wescott
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MA50570A publication Critical patent/MA50570A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA050570A 2017-11-08 2018-11-08 Formulations de fulvestrant et méthodes d'utilisation de ces dernières MA50570A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762583403P 2017-11-08 2017-11-08

Publications (1)

Publication Number Publication Date
MA50570A true MA50570A (fr) 2020-09-16

Family

ID=64650494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050570A MA50570A (fr) 2017-11-08 2018-11-08 Formulations de fulvestrant et méthodes d'utilisation de ces dernières

Country Status (15)

Country Link
US (1) US20230404918A1 (fr)
EP (1) EP3706719A1 (fr)
JP (1) JP7220712B2 (fr)
KR (1) KR102670293B1 (fr)
CN (1) CN111479556B (fr)
AU (1) AU2018366212B2 (fr)
BR (1) BR112020009141A2 (fr)
CA (1) CA3082193A1 (fr)
CO (1) CO2020006951A2 (fr)
IL (1) IL274433B2 (fr)
MA (1) MA50570A (fr)
MX (1) MX2020004792A (fr)
UA (1) UA128158C2 (fr)
WO (1) WO2019094650A1 (fr)
ZA (1) ZA202002897B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7497902B2 (ja) * 2019-12-11 2024-06-11 上海雲晟研新生物科技有限公司 フルベストラント医薬組成物、その調製方法及び応用
CN114617847A (zh) * 2020-12-10 2022-06-14 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用
WO2023121232A1 (fr) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 Composition pharmaceutique de fulvestrant ayant une solubilité améliorée, et son procédé de préparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
WO2003006064A1 (fr) * 2001-07-07 2003-01-23 Astrazeneca Ab Formulation pharmaceutique pour l'administration intramusculaire de fulvestrant
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
CN1857217A (zh) * 2006-03-28 2006-11-08 济南康泉医药科技有限公司 一种含雌激素受体拮抗剂的抗癌缓释注射剂
CN102014925B (zh) * 2008-03-07 2013-02-06 赛多斯有限责任公司 氟维司群配制剂
EP2460539A4 (fr) * 2009-07-31 2013-12-04 Xi An Libang Medical Technology Co Ltd Vecteur de médicament nanosphérique ou microsphérique, procédé de préparation, composition et utilisation de celui-ci
PT2616078T (pt) * 2010-09-16 2020-03-31 Shimoda Biotech Pty Ltd Composições de fulvestrant e métodos de uso
WO2013153559A1 (fr) * 2012-04-09 2013-10-17 Scidose, Llc Formulations de fulvestrant
EP3545968A1 (fr) * 2012-06-08 2019-10-02 F. Hoffmann-La Roche AG Sélectivité mutante et combinaisons d'un composé inhibiteur de phosphoinositide kinase 3 et d'agents chimiothérapeutiques pour le traitement du cancer
KR101782453B1 (ko) * 2013-07-08 2017-09-28 후아웨이 테크놀러지 컴퍼니 리미티드 비디오 재생 제어 방법, 장치 및 시스템
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (fr) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Compositions de fulvestrant
US20190134059A1 (en) * 2016-05-06 2019-05-09 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use

Also Published As

Publication number Publication date
WO2019094650A1 (fr) 2019-05-16
CN111479556B (zh) 2023-09-01
US20230404918A1 (en) 2023-12-21
AU2018366212A1 (en) 2020-05-14
UA128158C2 (uk) 2024-04-24
IL274433B1 (en) 2024-03-01
EP3706719A1 (fr) 2020-09-16
IL274433A (en) 2020-06-30
BR112020009141A2 (pt) 2020-10-27
KR20200085809A (ko) 2020-07-15
KR102670293B1 (ko) 2024-05-30
CA3082193A1 (fr) 2019-05-16
JP2021502362A (ja) 2021-01-28
JP7220712B2 (ja) 2023-02-10
CN111479556A (zh) 2020-07-31
RU2020118559A (ru) 2021-12-08
AU2018366212B2 (en) 2024-06-20
MX2020004792A (es) 2020-08-13
ZA202002897B (en) 2023-10-25
IL274433B2 (en) 2024-07-01
RU2020118559A3 (fr) 2021-12-08
CO2020006951A2 (es) 2020-06-19

Similar Documents

Publication Publication Date Title
MA54952A (fr) Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
DK3452448T3 (da) Modulatorer af den integrerede stressvej
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA47812A (fr) Composés interagissant avec le glycane et méthodes d'utilisation
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA43361A (fr) Composition pour le soin et la protection de cultures
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA54143A (fr) Compositions et méthodes
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
MA45602A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA53924A (fr) Modulateurs de l'expression d'apol1
FR3036598B1 (fr) Dispositif d'application et de massage
MA50570A (fr) Formulations de fulvestrant et méthodes d'utilisation de ces dernières